Onconetix SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 12, 2026, 6:05 a.m. ETView on SEC.gov
Submission of matters to a vote of security holders · Financial statements and exhibits
AI summary, unreviewedOnconetix, Inc. shareholders approve reverse split authority (1-for-2 to 1-for-15) and Series F PIPE conversion shares at 2026 annual meeting
8-KNov. 9, 2026, 8 a.m. ETView on SEC.gov Our explainer
Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedOnconetix (ONCO) Effects 1-for-10 Reverse Stock Split, Cutting Shares Outstanding to About 670,000
8-KNov. 5, 2026, 6:49 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedOnconetix amends Realbotix share exchange: Seller to own 95% of fully diluted shares if Net Cash is under $12.5 million; End Date extended to March 31, 2027
8-KOct. 26, 2026, 5:04 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedOnconetix (ONCO) Announces Second 1-for-10 Reverse Split, Aggregate 1-for-100 Effective November 6, 2026
8-KOct. 23, 2026, 11:40 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedOnconetix, Inc. Upsizes Realbotix Grid Note Draw to $3.0 Million Outstanding With $500,000 Advance
8-KSept. 14, 2026, 10:39 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
8-KJuly 29, 2026, 5:02 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Unregistered sales of equity securities · Financial statements and exhibits